NO20090203L - IL-8 receptorantagonist - Google Patents

IL-8 receptorantagonist

Info

Publication number: NO20090203L
Authority: NO; Norway
Prior art keywords: receptor antagonist; compositions; useful; treatment; relates
Prior art date: 2006-06-23

Application number

NO20090203A

Other languages

English (en)

Norwegian (no)

Inventor

Christopher S Brook

Jakob Busch-Petersen

Richard M Goodman

Edward C Webb

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-06-23

Filing date

2009-01-13

Publication date

2009-03-20

2009-01-13 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

2009-03-20 Publication of NO20090203L publication Critical patent/NO20090203L/no

Links

102000010681 interleukin-8 receptors Human genes 0.000 title 1
108010038415 interleukin-8 receptors Proteins 0.000 title 1
239000002464 receptor antagonist Substances 0.000 title 1
229940044551 receptor antagonist Drugs 0.000 title 1
102000004890 Interleukin-8 Human genes 0.000 abstract 2
108090001007 Interleukin-8 Proteins 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 abstract 1
229940096397 interleukin-8 Drugs 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Tropical Medicine & Parasitology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Toxicology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Virology (AREA)
Transplantation (AREA)
Endocrinology (AREA)
Hematology (AREA)
Vascular Medicine (AREA)

NO20090203A 2006-06-23 2009-01-13 IL-8 receptorantagonist NO20090203L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US80562606P	2006-06-23	2006-06-23
PCT/US2007/071866 WO2007150016A2 (fr)	2006-06-23	2007-06-22	Antagoniste du récepteur il-8

Publications (1)

Publication Number	Publication Date
NO20090203L true NO20090203L (no)	2009-03-20

Family

ID=38834411

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20090203A NO20090203L (no)	2006-06-23	2009-01-13	IL-8 receptorantagonist

Country Status (21)

Country	Link
US (2)	US20090281110A1 (fr)
EP (2)	EP2034832B1 (fr)
JP (3)	JP2009541352A (fr)
KR (1)	KR20090032097A (fr)
CN (1)	CN101505595A (fr)
AR (1)	AR061571A1 (fr)
AU (1)	AU2007260842B2 (fr)
BR (1)	BRPI0713304A2 (fr)
CA (1)	CA2655468A1 (fr)
CL (1)	CL2007001829A1 (fr)
CR (1)	CR10535A (fr)
EA (1)	EA015520B1 (fr)
ES (1)	ES2437115T3 (fr)
IL (1)	IL196056A0 (fr)
MA (1)	MA30528B1 (fr)
MX (1)	MX2009000162A (fr)
NO (1)	NO20090203L (fr)
NZ (1)	NZ573733A (fr)
PE (1)	PE20080943A1 (fr)
TW (1)	TW200817006A (fr)
WO (2)	WO2007150016A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200418812A (en)	2002-10-29	2004-10-01	Smithkline Beecham Corp	IL-8 receptor antagonists
CN104761637B (zh)	2006-03-31	2021-10-15	中外制药株式会社	调控抗体血液动力学的方法
PL2009992T3 (pl) *	2006-04-21	2012-11-30	Glaxosmithkline Llc	Antagoniści receptora IL-8
US8097626B2 (en)	2006-04-21	2012-01-17	Glaxosmithkline Llc	IL-8 receptor antagonists
JO2934B1 (en)	2006-06-23	2015-09-15	سميث كلاين بيتشام كوربوريشن	Prolyl hydroxylase inhibitors
CL2007001829A1 (es) *	2006-06-23	2008-01-25	Smithkline Beecham Corp	P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.
ES2595638T3 (es)	2007-09-26	2017-01-02	Chugai Seiyaku Kabushiki Kaisha	Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
KR102057826B1 (ko)	2008-04-11	2019-12-20	추가이 세이야쿠 가부시키가이샤	복수 분자의 항원에 반복 결합하는 항원 결합 분자
EP2278999B1 (fr)	2008-04-21	2025-01-29	Dompé farmaceutici S.p.A.	Préparations auriculaires de traitement de maladies et états otiques
US11969501B2 (en)	2008-04-21	2024-04-30	Dompé Farmaceutici S.P.A.	Auris formulations for treating otic diseases and conditions
EP2306975A4 (fr)	2008-07-21	2012-10-31	Otonomy Inc	Compositions à libération contrôlée modulant la structure otique et modulant le système immunitaire naturel et procédés de traitement de troubles otiques
EP2647706B1 (fr)	2010-11-30	2023-05-17	Chugai Seiyaku Kabushiki Kaisha	Molécule de liaison à l'antigène, apte à se lier de façon répétée à une pluralité de molécules d'antigène
WO2014030750A1 (fr)	2012-08-24	2014-02-27	中外製薬株式会社	ANTICORPS Fc SPÉCIFIQUE À FcyRII DE SOURIS
SG10201709559PA (en)	2012-08-24	2017-12-28	Chugai Pharmaceutical Co Ltd	Fcγriib-specific fc region variant
CN105246914B (zh)	2013-04-02	2021-08-27	中外制药株式会社	Fc区变体
KR101860280B1 (ko)	2014-12-19	2018-05-21	추가이 세이야쿠 가부시키가이샤	항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
KR102605798B1 (ko)	2015-02-05	2023-11-23	추가이 세이야쿠 가부시키가이샤	이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
WO2017110981A1 (fr)	2015-12-25	2017-06-29	Chugai Seiyaku Kabushiki Kaisha	Anticorps anti-myostatine et procédés d'utilisation
EP3494991A4 (fr) *	2016-08-05	2020-07-29	Chugai Seiyaku Kabushiki Kaisha	Composition pour la prophylaxie ou le traitement de maladies liées à il-8
SG10201607778XA (en)	2016-09-16	2018-04-27	Chugai Pharmaceutical Co Ltd	Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
CN110022897A (zh) *	2016-09-26	2019-07-16	Ｍｐｏ株式会社	卵子、受精卵或胚胎的质量改善剂
CN112119090B (zh)	2018-03-15	2023-01-13	中外制药株式会社	对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
WO2020218465A1 (fr) *	2019-04-26	2020-10-29	中外製薬株式会社	Procédé de diagnostic de l'endométriose, procédé de surveillance d'état de maladie et trousse
US20250312362A1 (en) *	2022-05-20	2025-10-09	Merck Sharp & Dohme Llc	INHIBITORS OF MsbA AS ANTIBIOTICS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
WO2025151629A2 (fr) *	2024-01-10	2025-07-17	The Children's Medical Center Corporation	Méthodes et compositions pour traiter des maladies associées à une inflammation, une douleur et/ou des lésions

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1792156A (en) *	1928-01-17	1931-02-10	Gen Aniline Works Inc	5-halogen-2-amino-1-alkyloxy and 1-aralkyloxy-benzenes and intermediate products thereof and process of preparing them
US2363074A (en) *	1938-06-16	1944-11-21	Geigy Ag J R	Halogen substituted acylamino sulphonic acids of the aromatic series and their manufacture
US2407309A (en) *	1942-02-04	1946-09-10	Squibb & Sons Inc	Chemotherapeutic agents of the sulphonamide type
US2353074A (en) *	1942-07-20	1944-07-04	Pratt Read & Company	Piano action
US2795610A (en) *	1955-03-31	1957-06-11	Du Pont	Hydroxy-phenyl alkyl ureas
US3065230A (en) *	1959-03-16	1962-11-20	Burroughs Wellcome Co	Azabicyclohexanes and method of preparing them
US3996253A (en) *	1966-01-11	1976-12-07	Minnesota Mining And Manufacturing Company	Process for the preparation of color images
SE370866B (fr) *	1968-03-21	1974-11-04	Ciba Geigy Ag
US3647819A (en) *	1969-09-19	1972-03-07	Sterling Drug Inc	Indazolylphenylureas and indazolyl-phenylthioureas
US4048333A (en) *	1971-08-23	1977-09-13	Medizinska Akademia	Method for treating a picorna virus infection
DE2303761A1 (de) *	1973-01-26	1974-08-01	Henkel & Cie Gmbh	Neue n,n'-disubstituierte thioharnstoffe, deren herstellung sowie verwendung als antimikrobielle substanzen
US4008326A (en) *	1973-12-26	1977-02-15	The Upjohn Company	Substituted ureas and thioureas and pharmaceutical compositions thereof
US3932434A (en) *	1974-08-30	1976-01-13	Eli Lilly And Company	N-2-(6-hydroxybenzothiazolyl)-N'-phenyl (or substituted phenyl) ureas
DE2928485A1 (de) *	1979-07-14	1981-01-29	Bayer Ag	Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
US4608205A (en) *	1983-03-09	1986-08-26	American Cyanamid Company	Polyanionic benzene ureas
US4591604A (en) *	1984-03-28	1986-05-27	American Cyanamid Company	Method of inhibiting the complement system by administering multisulfonated naphthalene ureas
US5215570A (en) *	1988-10-20	1993-06-01	Ciba-Geigy Corporation	Sulfamoylphenylureas
US5011937A (en) *	1988-11-14	1991-04-30	Ppg Industries, Inc.	Toluene sulfonate salts of 2-alkyl imidazolines
US5290814A (en) *	1988-11-21	1994-03-01	Burroughs Wellcome Co.	Anti-atherosclerotic diaryl compounds
US5206234A (en) *	1990-10-22	1993-04-27	Merck & Co., Inc.	Benzolactam analogs as antagonists of cck
JPH05294935A (ja) *	1991-03-15	1993-11-09	Green Cross Corp:The	アミノピリジン系化合物
US5552438A (en)	1992-04-02	1996-09-03	Smithkline Beecham Corporation	Compounds useful for treating allergic and inflammatory diseases
NZ250916A (en) *	1993-02-27	1995-08-28	Nihon Nohyaku Co Ltd	N-heteroaryl-n'-phenylureas, their use as acat inhibitors
DK41193D0 (da) *	1993-04-07	1993-04-07	Neurosearch As	Ionkanalaabnere
US5312831A (en) *	1993-05-12	1994-05-17	American Cyanamid Company	Urethanes and ureas that induce cytokine production
CA2123728A1 (fr) *	1993-05-21	1994-11-22	Noriyoshi Sueda	Derives de l'uree et leur utilisation comme inhibiteurs de l'acat
US5401758A (en) *	1993-10-07	1995-03-28	Bristol-Myers Squibb Company	Pyridinyl cyanoguanidine compounds
US5441984A (en) *	1994-01-06	1995-08-15	Eli Lilly And Company	Urea, thiourea and guanidine derivatives
US5576335A (en) *	1994-02-01	1996-11-19	Nisshin Flour Milling Co., Ltd.	Urea derivatives and their use as ACAT inhibitors
DE4413265A1 (de) *	1994-04-16	1995-10-19	Basf Ag	Hydroxyphenylharnstoffe
US5780483A (en) *	1995-02-17	1998-07-14	Smithkline Beecham Corporation	IL-8 receptor antagonists
JPH11503110A (ja) *	1995-02-17	1999-03-23	スミスクライン・ビーチャム・コーポレイション	Ｉｌ−８受容体拮抗剤
US6005008A (en) *	1996-02-16	1999-12-21	Smithkline Beecham Corporation	IL-8 receptor antagonists
US6211373B1 (en) *	1996-03-20	2001-04-03	Smithkline Beecham Corporation	Phenyl urea antagonists of the IL-8 receptor
US6262113B1 (en) *	1996-03-20	2001-07-17	Smithkline Beecham Corporation	IL-8 receptor antagonists
US6271261B1 (en) *	1996-06-27	2001-08-07	Smithkline Beecham Corporation	IL-8 receptor antagonists
CZ425598A3 (cs) *	1996-06-27	1999-08-11	Smithkline Beecham Corporation	Antagonista IL-8 receptoru
EP0932405A4 (fr) *	1996-06-27	2001-10-17	Smithkline Beckman Corp	Antagonistes des recepteurs d'il-8
EP0957907A4 (fr) *	1996-08-06	2001-08-16	Smithkline Beecham Corp	Antagonistes du recepteur de l'il-8
WO1998005329A1 (fr) *	1996-08-06	1998-02-12	Smithkline Beecham Corporation	Antagonistes du recepteur de l'interleukine-8 (il-8)
JP2000516621A (ja) *	1996-08-15	2000-12-12	スミスクライン・ビーチャム・コーポレイション	Ｉｌ―８レセプターアンタゴニスト
AR008290A1 (es) *	1996-08-15	1999-12-29	Smithkline Beecham Corp	Nuevos compuestos que contienen guanidina utiles como antagonistas de los receptores de il-8, composiciones farmaceuticas que los contienenprocedimiento para la preparacion de dichos compuestos y procedimiento para la preparacion de intermediarios.
JP2001501918A (ja) *	1996-08-21	2001-02-13	スミスクライン・ビーチャム・コーポレイション	Ｉｌ―８レセプターアンタゴニスト
US6133253A (en) *	1996-12-10	2000-10-17	Abbott Laboratories	3-Pyridyl enantiomers and their use as analgesics
US5929250A (en) *	1997-01-23	1999-07-27	Smithkline Beecham Corporation	IL-8 receptor antagonists
US6300325B1 (en) *	1997-01-23	2001-10-09	Smithkline Beecham Corporation	IL-8 receptor antagonists
US6436927B1 (en) *	1997-02-12	2002-08-20	Smithkline Beecham Corporation	IL-8 receptor antagonists
AR015426A1 (es) *	1997-09-05	2001-05-02	Smithkline Beecham Corp	Compuestos de benzotiazol antagonistas del receptor de il-8, composicion farmaceutica que los contiene, su uso para la manufactura de un medicamento,procedimiento para su preparacion, compuestos intermediarios y procedimiento para su preparacion
AR015425A1 (es) *	1997-09-05	2001-05-02	Smithkline Beecham Corp	Compuestos de benzotiazol, composicion farmaceutica que los contiene, su uso en la manufactura de un medicamento, procedimiento para su preparacion,compuestos intermediarios y procedimiento para su preparacion
EP1047424A4 (fr) *	1998-01-20	2002-05-22	Smithkline Beecham Corp	Antagonistes des recepteurs il-8
DE69908156T2 (de) *	1998-09-23	2003-12-24	Tularik, Inc.	Arylsulfonanilid-harnstoffe
UY25842A1 (es) *	1998-12-16	2001-04-30	Smithkline Beecham Corp	Antagonistas de receptores de il-8
AR029637A1 (es) *	1999-05-28	2003-07-10	Smithkline Beecham Corp	Compuestos de guanidina, antagonistas de los receptores de la il-8, una composicion farmaceutica que los contiene y el uso de los mismos para la manufactura de un medicamento
US20030225125A1 (en) *	1999-06-16	2003-12-04	Smithkline Beecham Corporation	IL-8 receptor antagonists
US6372933B1 (en) *	1999-08-26	2002-04-16	Smithkline Beecham Corporation	Process for preparing certain phenyl urea compounds
US6350751B1 (en) *	1999-10-11	2002-02-26	Pfizer Inc.	Therapeutic agents
US6440993B1 (en) *	1999-10-12	2002-08-27	Smithkline Beecham Corporation	IL-8 receptor antagonists
OA11558A (en)	1999-12-08	2004-06-03	Advanced Medicine Inc	Beta 2-adrenergic receptor agonists.
WO2001064165A2 (fr) *	2000-03-01	2001-09-07	Smithkline Beecham Corporation	Antagonistes du recepteur il-8
JP2004504270A (ja) *	2000-03-10	2004-02-12	スミスクライン・ビーチャム・コーポレイション	Ｉｌ−８受容体アンタゴニスト
MY133845A (en) *	2000-03-10	2007-11-30	Smithkline Beecham Corp	Il-8 receptor antagonists
US6767922B2 (en) *	2000-03-14	2004-07-27	Smithkline Beecham Corporation	IL-8 receptor antagonists
US6664259B2 (en) *	2000-03-16	2003-12-16	Smithkline Beecham Corporation	Il-8 receptor antagonists
UY26627A1 (es) *	2000-03-24	2001-09-28	Smithkline Beecham Corp	Antagonistas de receptores de il-8
US6653310B2 (en) *	2000-04-07	2003-11-25	Smithkline Beecham Corporation	IL-8 receptor antagonists
US6432960B2 (en) *	2000-05-10	2002-08-13	Bristol-Myers Squibb Company	Squarate derivatives of dihydropyridine NPY antagonists
CN1454204A (zh) *	2000-05-30	2003-11-05	史密丝克莱恩比彻姆公司	Il－8受体拮抗剂
DE60216229T2 (de) *	2001-01-16	2007-10-04	Smithkline Beecham Corp.	Il-8-rezeptorantagonisten
JP2004520412A (ja) *	2001-01-16	2004-07-08	スミスクライン・ビーチャム・コーポレイション	Ｉｌ−８受容体アンタゴニスト
WO2002076926A1 (fr) *	2001-02-02	2002-10-03	Schering Corporation	Composes de cyclobutene-1,2-diones 3,4-di-substitues en tant qu'antagonistes du recepteur de chimiokines cxc
US20030204085A1 (en) *	2001-02-02	2003-10-30	Taveras Arthur G.	3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists
GB0103630D0 (en)	2001-02-14	2001-03-28	Glaxo Group Ltd	Chemical compounds
US7144908B2 (en)	2001-03-08	2006-12-05	Glaxo Group Limited	Agonists of beta-adrenoceptors
ES2296923T3 (es)	2001-03-22	2008-05-01	Glaxo Group Limited	Derivados formanilidas como agonistas del adrenorreceptor beta2.
EP1383488A2 (fr) *	2001-03-30	2004-01-28	SmithKline Beecham Corporation	Procedes de synthese de composes contenant un phenol
EP1414810B1 (fr) *	2001-06-05	2006-08-30	Boehringer Ingelheim Pharmaceuticals Inc.	Composes de cycloalkyl uree condense avec un 1,4-disubstitue benzo
US20040038854A1 (en) *	2001-07-16	2004-02-26	Dillon Susan B.	Use of il-8 receptor antagonists in the treatment of virus infections
KR20090057477A (ko)	2001-09-14	2009-06-05	글락소 그룹 리미티드	호흡기 질환 치료용 펜에탄올아민 유도체
US6653323B2 (en)	2001-11-13	2003-11-25	Theravance, Inc.	Aryl aniline β2 adrenergic receptor agonists
GB0204719D0 (en)	2002-02-28	2002-04-17	Glaxo Group Ltd	Medicinal compounds
JP2005523920A (ja)	2002-04-25	2005-08-11	グラクソ　グループ　リミテッド	フェネタノールアミン誘導体
US20040029865A1 (en) *	2002-05-23	2004-02-12	Acker Brad A.	Bis-arylsulfones
GB0217225D0 (en)	2002-07-25	2002-09-04	Glaxo Group Ltd	Medicinal compounds
US20030032802A1 (en) *	2002-08-30	2003-02-13	Palovich Michael R.	IL8-receptor antagonists
US20030028042A1 (en) *	2002-08-30	2003-02-06	Palovich Michael R.	Il8-receptor antagonists
US20030065170A1 (en) *	2002-09-05	2003-04-03	Widdowson Katherine Louisa	Il-8 receptor antagonists
GB0220730D0 (en)	2002-09-06	2002-10-16	Glaxo Group Ltd	Medicinal compounds
GB0230045D0 (en)	2002-12-23	2003-01-29	Glaxo Group Ltd	Compounds
JP2006503108A (ja)	2002-09-16	2006-01-26	グラクソ　グループ　リミテッド	ピラゾロ［３，４−ｂ］ピリジン化合物およびそれのホスホジエステラーゼ阻害薬としての使用
EP1554264B1 (fr)	2002-10-22	2007-08-08	Glaxo Group Limited	Derives d'arylethanolamine a usage medicinal
GB0225030D0 (en)	2002-10-28	2002-12-04	Glaxo Group Ltd	Medicinal compounds
EP1556342B1 (fr)	2002-10-28	2008-03-26	Glaxo Group Limited	Derive de phenethanolamine utilise dans le traitement de maladies respiratoires
TW200418812A (en) *	2002-10-29	2004-10-01	Smithkline Beecham Corp	IL-8 receptor antagonists
GB0225535D0 (en)	2002-11-01	2002-12-11	Glaxo Group Ltd	Medicinal compounds
GB0225540D0 (en)	2002-11-01	2002-12-11	Glaxo Group Ltd	Medicinal compounds
TWI328009B (en)	2003-05-21	2010-08-01	Glaxo Group Ltd	Quinoline derivatives as phosphodiesterase inhibitors
JP2006527201A (ja) *	2003-06-06	2006-11-30	スミスクライン・ビーチャム・コーポレイション	Ｉｌ−８受容体アンタゴニスト
EP1663978B1 (fr) *	2003-07-23	2007-11-28	Bayer Pharmaceuticals Corporation	Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
AU2004299277A1 (en)	2003-12-19	2005-06-30	Glaxo Group Limited	Pyrazolo (3,4-b) pyridine compounds, and their use as phosphodiesterase inhibitors
US20080119471A1 (en) *	2004-02-24	2008-05-22	Ulrike Kaufmann	Piperazine urea derivatives for the treatment of endometriosis
GB0405933D0 (en)	2004-03-16	2004-04-21	Glaxo Group Ltd	Compounds
GB0405937D0 (en)	2004-03-16	2004-04-21	Glaxo Group Ltd	Compounds
US20080275078A1 (en)	2004-03-16	2008-11-06	Glaxo Group Limited	Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors
EP1812008A4 (fr) *	2004-10-20	2008-10-29	Smithkline Beecham Corp	Antagonistes du récepteur il-8
PL2009992T3 (pl) *	2006-04-21	2012-11-30	Glaxosmithkline Llc	Antagoniści receptora IL-8
CL2007001829A1 (es) *	2006-06-23	2008-01-25	Smithkline Beecham Corp	P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.

2007
- 2007-06-21 CL CL2007001829A patent/CL2007001829A1/es unknown
- 2007-06-21 AR ARP070102742A patent/AR061571A1/es not_active Application Discontinuation
- 2007-06-21 PE PE2007000793A patent/PE20080943A1/es not_active Application Discontinuation
- 2007-06-21 TW TW096122377A patent/TW200817006A/zh unknown
- 2007-06-22 KR KR1020097001495A patent/KR20090032097A/ko not_active Withdrawn
- 2007-06-22 NZ NZ573733A patent/NZ573733A/en not_active IP Right Cessation
- 2007-06-22 EA EA200970051A patent/EA015520B1/ru not_active IP Right Cessation
- 2007-06-22 CN CNA200780031405XA patent/CN101505595A/zh active Pending
- 2007-06-22 ES ES07812248.8T patent/ES2437115T3/es active Active
- 2007-06-22 MX MX2009000162A patent/MX2009000162A/es not_active Application Discontinuation
- 2007-06-22 JP JP2009516743A patent/JP2009541352A/ja not_active Withdrawn
- 2007-06-22 WO PCT/US2007/071866 patent/WO2007150016A2/fr not_active Ceased
- 2007-06-22 US US12/306,024 patent/US20090281110A1/en not_active Abandoned
- 2007-06-22 BR BRPI0713304-9A patent/BRPI0713304A2/pt not_active IP Right Cessation
- 2007-06-22 JP JP2009516744A patent/JP5711461B2/ja not_active Expired - Fee Related
- 2007-06-22 EP EP07812248.8A patent/EP2034832B1/fr active Active
- 2007-06-22 WO PCT/US2007/071864 patent/WO2007150015A2/fr not_active Ceased
- 2007-06-22 US US12/305,756 patent/US20090170871A1/en not_active Abandoned
- 2007-06-22 AU AU2007260842A patent/AU2007260842B2/en not_active Expired - Fee Related
- 2007-06-22 CA CA002655468A patent/CA2655468A1/fr not_active Abandoned
- 2007-06-22 EP EP07798924A patent/EP2032131A4/fr not_active Withdrawn
2008
- 2008-12-18 CR CR10535A patent/CR10535A/es not_active Application Discontinuation
- 2008-12-18 IL IL196056A patent/IL196056A0/en unknown
- 2008-12-24 MA MA31504A patent/MA30528B1/fr unknown
2009
- 2009-01-13 NO NO20090203A patent/NO20090203L/no not_active Application Discontinuation
2013
- 2013-10-18 JP JP2013217294A patent/JP2014055145A/ja active Pending

Also Published As

Publication number	Publication date
AR061571A1 (es)	2008-09-03
CR10535A (es)	2009-03-20
MA30528B1 (fr)	2009-06-01
EP2032131A4 (fr)	2009-09-02
ES2437115T3 (es)	2014-01-09
WO2007150015A3 (fr)	2008-02-28
AU2007260842A1 (en)	2007-12-27
PE20080943A1 (es)	2008-09-27
CN101505595A (zh)	2009-08-12
EP2034832A4 (fr)	2010-12-08
KR20090032097A (ko)	2009-03-31
AU2007260842B2 (en)	2012-03-15
JP2014055145A (ja)	2014-03-27
JP2009541353A (ja)	2009-11-26
US20090281110A1 (en)	2009-11-12
EP2032131A2 (fr)	2009-03-11
WO2007150016A3 (fr)	2008-12-04
EA015520B1 (ru)	2011-08-30
US20090170871A1 (en)	2009-07-02
BRPI0713304A2 (pt)	2012-04-17
JP2009541352A (ja)	2009-11-26
TW200817006A (en)	2008-04-16
EP2034832B1 (fr)	2013-10-02
NZ573733A (en)	2011-03-31
EP2034832A2 (fr)	2009-03-18
CL2007001829A1 (es)	2008-01-25
EA200970051A1 (ru)	2009-06-30
JP5711461B2 (ja)	2015-04-30
IL196056A0 (en)	2009-09-01
MX2009000162A (es)	2009-01-23
WO2007150016A2 (fr)	2007-12-27
CA2655468A1 (fr)	2007-12-27
WO2007150015A2 (fr)	2007-12-27

Legal Events

Date	Code	Title	Description
2013-02-04	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20090203L (no)	2009-03-20	IL-8 receptorantagonist
JO2796B1 (en)	2014-03-15	Antiallergic drugs IL-8
WO2007124423A3 (fr)	2009-04-09	Antagonistes du récepteur de l'il-8
ATE500250T1 (de)	2011-03-15	Azetidinverbindungen als orexin-rezeptor- antagonisten
NO20092652L (no)	2009-09-11	Konstruert anti-TSLP-antistoff
ATE469895T1 (de)	2010-06-15	Cgrp-rezeptorantagonisten
ATE484505T1 (de)	2010-10-15	5-sulfanylmethylä1,2,4ütriazolä1,5-aüpyrimidin- - olderivate als cxcr2-antagonisten
MX2009005363A (es)	2009-06-05	Pirimidinas y su uso como antagonistas del receptor cxcr2.
DK2035379T3 (da)	2010-09-06	Inhibitorer af 11-beta-hydroxysteroiddehydrogenase 1
EA200970342A1 (ru)	2009-10-30	Антагонисты рецептора глюкагона, композиции, содержащие такие соединения, и способы применения
PA8713501A1 (es)	2009-09-17	INHIBIDORES DE 11-BETA HIDROXIESTEROIDE DEHIDROGENASA - 11ßHSD1
DK2049513T3 (da)	2012-02-27	Piperidinylsubstituerede pyrrolidinoner som inhibitorer af 11-beta-hydroxysteroiddehydrogenase 1
DK2021336T3 (da)	2010-09-13	11-beta-hydroxysteroid-dehydrogenase-1-inhibitorer
DK2049475T3 (da)	2012-03-05	Cyclohexyl-substituerede pyrrolidinoner som inhibitorer af 11-beta-hydroxysteroid dehydrogenase1
EP1868628A4 (fr)	2009-12-02	Composes, compositions et methodes de traitement des infections a poxvirus
ATE455110T1 (de)	2010-01-15	11-beta-hydroxysteroid-dehydrogenase-1-hemmer
DE602007012072D1 (de)	2011-03-03	Orantagonisten
ATE435206T1 (de)	2009-07-15	Heteroarylsulfonylstilbene als 5-ht2a- antagonisten
ATE419845T1 (de)	2009-01-15	Il-8-rezeptor-antagonisten
EA200870515A1 (ru)	2009-06-30	Моноциклические гетероарильные соединения
EP1986849A4 (fr)	2013-12-11	Compositions supprimant la combustion, resistantes au lavage
WO2005000231A3 (fr)	2005-05-12	Antagonistes du recepteur il-8
WO2001068568A3 (fr)	2002-03-21	Antagonistes du recepteur de il-8
WO2001068569A3 (fr)	2002-04-18	Antagonistes du recepteur de il-8
ATE474834T1 (de)	2010-08-15	Als agonisten des gpr38-rezeptors geeignete biarylverbindungen